Compound 121564

Developed for: non-small cell lung carcinoma
Investigated by: Arafat Tfayli · Merck KGaA, Darmstadt, Germany · Phoenix Clinical Research

today NCT03480230 · Ph 2

20192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT03480230	Jun 2018 → Nov 2022	non-small cell lung carcinoma	Arafat Tfayli	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Compound 121564	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03480230 ↗
Route	Intravenous	“given intravenously” NCT03480230 ↗